<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2954-4122</journal-id>
<journal-title><![CDATA[Archivos de neurociencias (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Neurocien. (Mex.)]]></abbrev-journal-title>
<issn>2954-4122</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez"]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2954-41222023000300007</article-id>
<article-id pub-id-type="doi">10.31157/an.v28i3.399</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación del efecto antioxidante de la olanzapina en combinación con n acetilcisteína en un modelo de esquizofrenia inducido por mk-801 en ratón]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lamas-Aguilar]]></surname>
<given-names><![CDATA[Reyna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Neri]]></surname>
<given-names><![CDATA[Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ríos]]></surname>
<given-names><![CDATA[Camilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mata-Bermúdez]]></surname>
<given-names><![CDATA[Alfonso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Erick]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Manning]]></surname>
<given-names><![CDATA[Norman]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Diaz-Ruiz]]></surname>
<given-names><![CDATA[Araceli]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez Departamento de Neuroquímica ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma Metropolitana  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>28</volume>
<numero>3</numero>
<fpage>7</fpage>
<lpage>14</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2954-41222023000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2954-41222023000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2954-41222023000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La esquizofrenia es una condición crónica que afecta a 1% de la población. Una de las principales teorías sobre su etiología señala que la hipofunción en los receptores de glutamato N-metil-D-aspartato (NMDA) induce la pérdida del equilibrio entre la producción de especies oxidantes generadas en el metabolismo celular y los sistemas de defensa antioxidante, lo que genera un estado de estrés oxidante. Se ha propuesto a la N-acetilcisteína (NAC) como un agente adyuvante para potencializar la eficacia de antipsicóticos atípicos como la olanzapina (OLZ), mejorando los procesos de oxidación propios de la enfermedad.  Métodos: Se utilizaron 30 ratones divididos en cinco grupos experimentales, a los cuales se administró MK-801 (un antagonista de NMDA) como modelo de esquizofrenia. Se evalúo la participación del estrés oxidante al medir la peroxidación lipídica y la concentración de glutatión reducido a nivel de la corteza frontal.  Resultados: La administración de MK-801 produjo aumento en la peroxidación lipídica y disminución en la concentración de glutatión reducido a nivel de la corteza frontal. Tanto los tratamientos de OLZ y NAC, administrados solos o en combinación, disminuyeron la peroxidación lipídica y aumentaron el glutatión reducido en la corteza frontal.  Discusión: Estos datos sugieren que el tratamiento con OLZ y NAC, administradas solas o en combinación, regulan el daño oxidante propio de la enfermedad y podrían ser una opción para pacientes con psicosis crónica o con poca respuesta a los esquemas actuales de tratamiento. Sin embargo, se requieren más estudios para demostrar su eficacia y seguridad.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[modelo de esquizofrenia]]></kwd>
<kwd lng="es"><![CDATA[MK-801]]></kwd>
<kwd lng="es"><![CDATA[olanzapina]]></kwd>
<kwd lng="es"><![CDATA[N-acetilcisteína]]></kwd>
<kwd lng="es"><![CDATA[lipoperoxidación]]></kwd>
<kwd lng="es"><![CDATA[glutatión reducido]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charlson]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Santomauro]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Diminic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stockings]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016]]></article-title>
<source><![CDATA[Schizophr Bull]]></source>
<year>2018</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1195-203</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jablensky]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of schizophrenia: the Global Burden of Disease and disability]]></article-title>
<source><![CDATA[Eur Arch Psychiatry Clin Neurosci]]></source>
<year>2000</year>
<volume>250</volume>
<page-range>274-85</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGrath]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chant]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Welham]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schizophrenia: a concise overview of incidence, prevalence, and mortality]]></article-title>
<source><![CDATA[Epidemiol Rev]]></source>
<year>2008</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-76</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCutcheon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Howes]]></surname>
<given-names><![CDATA[OD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schizophrenia-an overview]]></article-title>
<source><![CDATA[JAMA Psychiatry]]></source>
<year>2020</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>201-10</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laursen]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Nordentoft]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[PB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Excess early mortality in schizophrenia]]></article-title>
<source><![CDATA[Annu Rev Clin Psychol]]></source>
<year>2014</year>
<volume>10</volume>
<page-range>425-48</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hjorthøj]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stürup]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[McGrath]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nordentoft]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet Psychiatry]]></source>
<year>2017</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>295-301</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charlson]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baxter]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dua]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Degenhardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Whiteford]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010]]></article-title>
<source><![CDATA[Epidemiol Psychiatr Sci]]></source>
<year>2015</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>121-40</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aquino-Miranda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Ramírez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez-Gómez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Escamilla-Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González-Pantoja]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Languren]]></surname>
<given-names><![CDATA[L-E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histamine H3 receptor activation reduces the impairment in prepulse inhibition (PPI) of the acoustic startle response and Akt phosphorylation induced by MK-801 (dizocilpine), antagonist at N-Methyl-d-Aspartate (NMDA) receptors]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2019</year>
<volume>94</volume>
<numero>109653</numero>
<issue>109653</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakazawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sapkota]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The origin of NMDA receptor hypofunction in schizophrenia]]></article-title>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2020</year>
<volume>205</volume>
<page-range>107426</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slifstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van de Giessen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Van Snellenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Narendran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study]]></article-title>
<source><![CDATA[JAMA Psychiatry]]></source>
<year>2015</year>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>316-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[JD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An integrative theory of prefrontal cortex function]]></article-title>
<source><![CDATA[Annu Rev Neurosci]]></source>
<year>2001</year>
<volume>24</volume>
<page-range>167-202</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The meaning of &#8216;life&#8217; and other abstract words: Insights from neuropsychology]]></article-title>
<source><![CDATA[J Neuropsychol]]></source>
<year>2016</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>317-43</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yücel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pantelis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress]]></source>
<year>2009</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
<name>
<surname><![CDATA[Coronado]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Putative neuroprotective pharmacotherapies to target the staged progression of mental illness]]></article-title>
<source><![CDATA[Early Interv Psychiatry]]></source>
<year>2019</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1032-49</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moylan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Samuni]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Neil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oxidative &amp; nitrosative stress in depression: Why so much stress?]]></article-title>
<source><![CDATA[Neurosci Biobehav Rev]]></source>
<year>2014</year>
<volume>45</volume>
<page-range>46-62</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halliwell]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of free radicals in the neurodegenerative diseases]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2001</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>685-716</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bavarsad Shahripour]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Harrigan]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Alexandrov]]></surname>
<given-names><![CDATA[AV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities]]></article-title>
<source><![CDATA[Brain Behav]]></source>
<year>2014</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>108-22</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andreazza]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Valvassori]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Zanotto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Comim]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DNA damage in rats after treatment with methylphenidate]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2007</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1282-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[L-J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J-H]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Murugan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis]]></article-title>
<source><![CDATA[Oxid Med Cell Longev]]></source>
<year>2019</year>
<volume>2019</volume>
<page-range>5080843</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Que]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[M-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yeang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gonen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Prohaska]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolemic mice]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2018</year>
<volume>558</volume>
<numero>7709</numero>
<issue>7709</issue>
<page-range>301-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[AI.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glutathione: a novel treatment target in psychiatry]]></article-title>
<source><![CDATA[Trends Pharmacol Sci]]></source>
<year>2008</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>346-51</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creese]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Burt]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[SH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs]]></article-title>
<source><![CDATA[Science]]></source>
<year>1976</year>
<volume>192</volume>
<numero>4238</numero>
<issue>4238</issue>
<page-range>481-3</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaar]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Natesan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McCutcheon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Howes]]></surname>
<given-names><![CDATA[OD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology]]></article-title>
<source><![CDATA[Neuropharmacology]]></source>
<year>2020</year>
<volume>172</volume>
<page-range>107704</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaquero-Baez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Ruíz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tristán-López]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aviña-Cervantes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Bermúdez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia]]></article-title>
<source><![CDATA[BMC Psychiatry]]></source>
<year>2019</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>295</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lowe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Krivoy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Porffy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Henriksdottir]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Eromona]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shergill]]></surname>
<given-names><![CDATA[SS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When the drugs don&#8217;t work: treatment-resistant schizophrenia, serotonin and serendipity]]></article-title>
<source><![CDATA[Ther Adv Psychopharmacol]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63-70</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Komossa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rummel&#8208;Kluge]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hunger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schwarz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Duggan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Olanzapine versus other atypical antipsychotics for schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2010</year>
<numero>3</numero>
<issue>3</issue>
<page-range>CD006654</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fulton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Goa]]></surname>
<given-names><![CDATA[KL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1997</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>281-98</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bernardo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de olanzapina en el tratamiento de la esquizofrenia y el trastorno bipolar]]></article-title>
<source><![CDATA[Psiquiatr Biológica]]></source>
<year>2016</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-22</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atmaca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuloglu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ustundag]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2003</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>598-604</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Monim]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Neill]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm]]></article-title>
<source><![CDATA[Behav Brain Res]]></source>
<year>2006</year>
<volume>169</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>263-73</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goetghebeur]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study]]></article-title>
<source><![CDATA[Psychopharmacology (Berl)]]></source>
<year>2009</year>
<volume>202</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>287-93</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential effects of olanzapine and haloperidol on MK-801-induced memory impairment in mice]]></article-title>
<source><![CDATA[Clin Psychopharmacol Neurosci]]></source>
<year>2016</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>279-85</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Olanzapine reverses MK-801-induced cognitive deficits and region-specific alterations of NMDA receptor subunits]]></article-title>
<source><![CDATA[Front Behav Neurosci]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>260</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal neuronal cultures]]></article-title>
<source><![CDATA[Synap NYN]]></source>
<year>2013</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>224-34</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnamurthy]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repeated olanzapine treatment mitigates PTSD like symptoms in rats with changes in cell signaling factors]]></article-title>
<source><![CDATA[Brain Res Bull]]></source>
<year>2018</year>
<volume>140</volume>
<page-range>365-77</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boz]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[XF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-acetylcysteine prevents olanzapineinduced oxidative stress in mHypoA-59 hypothalamic neurons]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>19185</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scalley]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[CS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acetaminophen poisoning: a case report of the use of acetylcysteine]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1978</year>
<volume>35</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>964-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Copolov]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Malhi]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2008</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1955-62</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossell]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Galletly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Siskind]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N -acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double-blind randomised placebo controlled trial targeting negative symptoms]]></article-title>
<source><![CDATA[BMC Psychiatry]]></source>
<year>2016</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deepmala]]></surname>
<given-names><![CDATA[Slattery J]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar N]]></surname>
<given-names><![CDATA[Delhey L]]></given-names>
</name>
<name>
<surname><![CDATA[Berk M]]></surname>
<given-names><![CDATA[Dean O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review]]></article-title>
<source><![CDATA[Neurosci Biobehav Rev]]></source>
<year>2015</year>
<volume>55</volume>
<page-range>294-321</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerksick]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Willoughby]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The antioxidant role of glutathione and N-Acetyl-Cysteine supplements and exercise-induced oxidative stress]]></article-title>
<source><![CDATA[J Int Soc Sports Nutr]]></source>
<year>2005</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Giorlando]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action]]></article-title>
<source><![CDATA[J Psychiatry Neurosci]]></source>
<year>2011</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>78-86</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quintavalle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Donnarumma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fiore]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Briguori]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Condorelli]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic strategies to prevent contrast-induced acute kidney injury]]></article-title>
<source><![CDATA[Curr Opin Cardiol]]></source>
<year>2013</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>676-82</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kennar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Uetrecht]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of clozapine and olanzapine on neutrophil kinetics: Implications for drug-induced agranulocytosis]]></article-title>
<source><![CDATA[Chem Res Toxicol]]></source>
<year>2014</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1104-8</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Triggs]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Willmore]]></surname>
<given-names><![CDATA[LJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vivo lipid peroxidation in rat brain following intracortical Fe2+ injection]]></article-title>
<source><![CDATA[J Neurochem]]></source>
<year>1984</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>976-80</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz-Ruiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rios]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Guizar-Sahagun]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grijalva]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclosporin-A inhibits lipid peroxidation after spinal cord injury in rats]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>1999</year>
<volume>266</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>61-4</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz-Ruiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alcaraz-Zubeldia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[SalgadoCeballos]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mendez-Armenta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rios]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential time-course of the increase of antioxidant thiol-defenses in the acute phase after spinal cord injury in rats]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>2009</year>
<volume>452</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-9</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[W&#261;sik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bia&#322;o&#324;]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jantas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[&#379;arnowska]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of the combined administration of 1MeTIQ and MK-801 on cell viability, oxidative stress markers, and glutamate release in the rat hippocampus]]></article-title>
<source><![CDATA[Neurotox Res]]></source>
<year>2021</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1747-61</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozyurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ozyurt]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Akpolat]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Erdogan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sarsilmaz]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2007</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>832-8</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turkmen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Akosman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Demirel]]></surname>
<given-names><![CDATA[HH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protective effect of N-acetylcysteine on MK-801-induced testicular oxidative stress in mice]]></article-title>
<source><![CDATA[Biomed Pharmacother]]></source>
<year>2019</year>
<volume>109</volume>
<page-range>1988-93</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smaga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pomierny]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Krzy&#380;anowska]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Pomierny-Chamio&#322;o]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Miszkiel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Niedzielska]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: Behavioral and biochemical analyses in rats]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2012</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>280-7</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nucifora]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry]]></article-title>
<source><![CDATA[Transl Psychiatry]]></source>
<year>2017</year>
<volume>7</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Do]]></surname>
<given-names><![CDATA[KQ]]></given-names>
</name>
<name>
<surname><![CDATA[Trabesinger]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Kirsten&#8208;Krüger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lauer]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dydak]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Hell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo]]></article-title>
<source><![CDATA[Eur J Neurosci]]></source>
<year>2000</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3721-8</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Mancuso]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Copolov]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Do]]></surname>
<given-names><![CDATA[KQ]]></given-names>
</name>
<name>
<surname><![CDATA[Cuénod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia]]></article-title>
<source><![CDATA[Psychiatry Res]]></source>
<year>2015</year>
<volume>230</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>982-3</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
